[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600509":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":27,"studyPopulation":28,"armGroups":23,"interventions":23,"overallOfficials":23,"centralContacts":29,"locations":38,"responsibleParty":53,"collaborators":23,"id":56,"slug":23,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":23,"enrollmentInfo":65,"targetDuration":23,"studyType":68,"phases":23,"briefSummary":69,"conditions":70,"keywords":23,"overallStatus":71,"whyStopped":23,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":23},[9,13],{"measure":10,"description":11,"timeFrame":12},"Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China.","Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China will beperformed to assess the proportions of CKD primary diseases, distribution of CKD stages, baseline Hb level distribution, and proportion of anti-anemia medication usage.","20230101-20241231",{"measure":14,"description":15,"timeFrame":12},"Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.)","An analysis will be performed to assess the safety according to CTCAE 5.0 .",[17,20],{"measure":18,"description":19,"timeFrame":12},"Analyze the efficacy of different anemia drugs in CKD patients with anemia.","Use the hemoglobin level to analyze the efficacy of different anemia drugs in CKD patients with anemia.",{"measure":21,"description":22,"timeFrame":12},"Explore the economic burden of anemia in CKD patients","Use the annual cost to explore the direct economic burden of anemia in CKD patients.",null,{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":25,"timePerspective":26,"maskingInfo":23},"COHORT","RETROSPECTIVE","Anemia adversely affects the quality of life of CKD patients and increases the risk of CKD progression.\n\nThis study utilize data from approximately 20 medical centers across China. It aims to:\n\n1. Analyze the disease characteristics, current diagnostic and treatments in Chinese patients with CKD-anemia.\n2. Evaluate the safety and efficacy profiles of different drugs used for CKD-anemia.\n3. Explore the direct medical costs associated with CKD-anemia management within real-world clinical practice in China.","Anemia in Chronic Kidney Disease",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":23,"email":34},"Wei Chen","CONTACT","8602087769673","chenwei99@mail.sysu.edu.cn",{"name":36,"role":32,"phone":33,"phoneExt":23,"email":37},"Zhong Zhong","zhongzh55@mail.sysu.edu.cn",[39],{"facility":5,"status":23,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Guangzhou","Guangdong","510080","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52],{"name":36,"role":32,"phone":33,"phoneExt":23,"email":37},{"type":54,"investigatorFullName":31,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Doctor","100600509",false,"NCT07098416","A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）","An In-Depth Analysis of the Present Diagnostic and Therapeutic Landscape for Renal Anemia in China's Real-World Clinical Environment: A Multicenter Retrospective Cohort Investigation（DASHENG Study）","DASHENG","Inclusion Criteria: CKD patients will be defined as those meeting any of the following criteria during the observation period:\n\n1. diagnosis of CKD (e.g., \"%chronic kidney disease%\", \"%chronic nephropathy%\", \"%renal failure%\", \"%nephritis%\" for complete ICD-9\u002F10 code mapping\\*)\n2. record of hemodialysis (HD) or peritoneal dialysis (PD) (refer to Attachment 2 for dialysis identification algorithms)\n3. ≥2 eGFR measurements \\\u003C60 mL\u002Fmin\u002F1.73m² (calculated using CKD-EPI equation) with ≥3-month interval (excluding acute kidney injury)\n\nExclusion Criteria:\n\n1. Non-renal anemia due to trauma, traffic accidents, major hemorrhage, or other confirmed etiologies (e.g., acute hemorrhagic anemia, nutritional deficiency anemia, hemolytic anemia);\n2. Diagnosis of acute kidney disease (AKD) without chronic kidney disease (CKD) comorbidity;\n3. Incomplete critical data elements (including age, sex, or visit dates).","ALL","18 Years",{"count":66,"type":67},20000,"ESTIMATED","OBSERVATIONAL","Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.",[28],"NOT_YET_RECRUITING","2025-07-31",{"date":74,"type":75},"2025-08-01","ACTUAL",{"date":74,"type":67},{"date":78,"type":67},"2027-08-31",{"name":31,"class":6},1]